X
KEY SERVICES
International Enquiries: international@usv.in
Business Development: biz.dev@usv.in
General Requests: info@usv.in
Website: http://www.usvindia.com/
Details:
Under the partnership, USV and Biogenomics launched Insuquick, India's first biosimilar insulin aspart, a rapid-acting analogue of insulin, for the treatment of diabetes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Insuquick
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Biogenomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2023
Details:
Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Linagliptin
Therapeutic Area: Endocrinology Product Name: Liralin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2023
Details:
Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.
Lead Product(s): Rosuvastatin,Clopidogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Roseday CV
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Jalra-Trio (vildagliptin + dapagliflozin + metformin) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Vildagliptin,Dapagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Jalra Trio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Details:
Pioz V (vildagliptin + pioglitazone) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Vildagliptin,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Pioz V
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.
Lead Product(s): Vildagliptin
Therapeutic Area: Endocrinology Product Name: Jalra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
